These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Khanam S; Pilankatta R; Khanna N; Swaminathan S Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609 [TBL] [Abstract][Full Text] [Related]
5. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4 Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB Front Immunol; 2019; 10():59. PubMed ID: 30761131 [TBL] [Abstract][Full Text] [Related]
6. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes. Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892 [TBL] [Abstract][Full Text] [Related]
7. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence. Sun J; Li M; Wang Y; Hao P; Jin X Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441 [TBL] [Abstract][Full Text] [Related]
15. Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems. Gottschamel J; Lössl A; Ruf S; Wang Y; Skaugen M; Bock R; Clarke JL Plant Mol Biol; 2016 Jul; 91(4-5):497-512. PubMed ID: 27116001 [TBL] [Abstract][Full Text] [Related]
16. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Etemad B; Batra G; Raut R; Dahiya S; Khanam S; Swaminathan S; Khanna N Am J Trop Med Hyg; 2008 Sep; 79(3):353-63. PubMed ID: 18784226 [TBL] [Abstract][Full Text] [Related]
17. Challenges for the formulation of a universal vaccine against dengue. Chokephaibulkit K; Perng GC Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907 [TBL] [Abstract][Full Text] [Related]
18. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design. Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764 [TBL] [Abstract][Full Text] [Related]
19. Immune response to dengue virus and prospects for a vaccine. Murphy BR; Whitehead SS Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187 [TBL] [Abstract][Full Text] [Related]
20. Simple production of hydrophobin-fused domain III of dengue envelope protein and induction of neutralizing antibodies against the homotypic serotype of dengue virus. Cerezo J; Targovnik AM; Smith ME; González Maglio D; Luppo VC; Morales MA; Miranda MV; Rodríguez Talou J Biotechnol Lett; 2020 Mar; 42(3):419-428. PubMed ID: 31828570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]